Disease impact in chronic progressive external ophthalmoplegia: more than meets the eye

Neuromuscul Disord. 2011 Apr;21(4):272-8. doi: 10.1016/j.nmd.2010.12.008. Epub 2011 Jan 13.

Abstract

We determined the extent of disease impact in 28 patients with genetically confirmed chronic progressive external ophthalmoplegia (CPEO) and compared the outcomes to those of matched myotonic dystrophy type I patients. CPEO patients reported a high frequency of severe fatigue (67.9%), pain (96.2%), depression (32.1%) and dependency in daily life (46.4%). The frequency and extent of depression were significantly higher than in DM1 patients (32.1% vs. 7.1%, p=0.040; mean Beck's depression inventory for primary care score 3.8±3.5 vs. 1.3±1.4, p=0.001), as were fatigue severity, pain intensity and extent of functional impairments. CPEO patients with polymerase gamma-1 mutations reported more functional impairments than those with mitochondrial DNA mutations. Disease impact was however not influenced by most clinical features. The present results help physicians to identify and to treat the factors that influence quality of life in CPEO patients and to provide symptomatic treatment where needed.

MeSH terms

  • Activities of Daily Living
  • Adult
  • Age of Onset
  • Aged
  • Chronic Disease
  • DNA Polymerase gamma
  • DNA, Mitochondrial / genetics
  • DNA-Directed DNA Polymerase / genetics
  • Depression / etiology
  • Eye / pathology*
  • Fatigue / etiology
  • Fatigue / psychology
  • Female
  • Humans
  • Independent Living
  • Male
  • Middle Aged
  • Mutation / physiology
  • Myotonic Dystrophy / complications
  • Myotonic Dystrophy / psychology
  • Odds Ratio
  • Ophthalmoplegia / complications*
  • Ophthalmoplegia / psychology
  • Pain / etiology
  • Pain Measurement
  • Psychiatric Status Rating Scales
  • Quality of Life
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • DNA, Mitochondrial
  • DNA Polymerase gamma
  • DNA-Directed DNA Polymerase
  • POLG protein, human